DNAmito said it has acquired ptTheragnostic (PTT) in Maastricht, Netherlands. PTT is a spin-off from the Maastricht University, University Medical Center and Maastro Clinic.
No financial details were disclosed.
The company is focused on the development of genomics-based personalized analysis for radiation sensitivity to optimize radiation treatment for cancer as well as chronic disease risk prediction. The saliva-based genomics tests are integrated in multifactorial Clinical Decision Support Systems.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze